{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T17:15:02Z","timestamp":1649178902622},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,1,30]],"date-time":"2009-01-30T00:00:00Z","timestamp":1233273600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1007\/s00105-008-1662-4","type":"journal-article","created":{"date-parts":[[2009,1,28]],"date-time":"2009-01-28T12:01:19Z","timestamp":1233144079000},"page":"91-99","source":"Crossref","is-referenced-by-count":1,"title":["Behandlungsstrategien bei Psoriasis vulgaris und Psoriasisarthritis"],"prefix":"10.1007","volume":"60","author":[{"given":"G.","family":"Wozel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,1,30]]},"reference":[{"key":"1662_CR1","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2133.2008.08563.x","volume":"158","author":"Brauchli","year":"2008","unstructured":"Brauchli YB, Jick SS, Curtin F, Meier CR (2008) Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study. Br J Dermatol 158:1299\u20131307","journal-title":"Br J Dermatol"},{"key":"1662_CR2","unstructured":"Capon F, Trembath RC, Barker JN (2004) An update on the genetics of psoriasis. In: Thiers BH, Menter A, Cather J (eds) Dermatologic Clinics. Psoriasis. Elsevier, Pennsylvania, 22:339\u2013347"},{"key":"1662_CR3","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/art.23104","volume":"57","author":"Chandran","year":"2007","unstructured":"Chandran V, Schentag CT, Gladmann D (2007) Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum 57:1560\u20131563","journal-title":"Arthritis Rheum"},{"key":"1662_CR4","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/archderm.138.6.791","volume":"138","author":"Creamer","year":"2002","unstructured":"Creamer D, Allen MH, Jaggar R et al (2002) Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol 138:791\u2013796","journal-title":"Arch Dermatol"},{"key":"1662_CR5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"Finlay","year":"1994","unstructured":"Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI) \u2013 a simple practical measure for routine clinical use. Clin Exp Dermatol 19:210\u2013216","journal-title":"Clin Exp Dermatol"},{"key":"1662_CR6","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2005.06502.x","volume":"152","author":"Finlay","year":"2005","unstructured":"Finlay AY (2005) Current severe psoriasis and the rules of tens. Br J Dermatol 152:861\u2013867","journal-title":"Br J Dermatol"},{"key":"1662_CR7","first-page":"223","volume":"143","author":"de","year":"2007","unstructured":"de Gannes GC, Ghoreishi M, Pope J et al (2007) Psoriasis and pustular dermatitis triggered by TNF-\u03b1 inhibitions in patients with rheumatologic conditions. Arch Dermatol 143:223\u2013231","journal-title":"Arch Dermatol"},{"key":"1662_CR8","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","volume":"296","author":"Gelfand","year":"2006","unstructured":"Gelfand JM, Neimann AL, Shin DB et al (2006) Risk of myocardial infarction in patients with psoriasis. J Am Med Assoc 296:1735\u20131741","journal-title":"J Am Med Assoc"},{"key":"1662_CR9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2133.2007.07986.x","volume":"157","author":"Gisondi","year":"2007","unstructured":"Gisondi P, Tessari G, Conti A et al (2007) Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 157:68\u201373","journal-title":"Br J Dermatol"},{"key":"1662_CR10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000104261","volume":"215","author":"Kalayciyan","year":"2007","unstructured":"Kalayciyan A, Aydemir EH, Kotogyan A (2007) Experimental Koebner phenomenon in patients with psoriasis. Dermatology 215:114\u2013117","journal-title":"Dermatology"},{"key":"1662_CR11","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/art.23383","volume":"58","author":"Kay","year":"2008","unstructured":"Kay J, Matteson EL, Dasgupta B et al (2008) Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate. Arthritis Rheum 58:964\u2013975","journal-title":"Arthritis Rheum"},{"key":"1662_CR12","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/archdermatol.2007.63","volume":"144","author":"Kimball","year":"2008","unstructured":"Kimball AB, Gordon KB, Langley RG et al (2008) Safety and efficacy of ABT-874, a fully human interleukin 12\/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis. Arch Dermatol 144:200\u2013207","journal-title":"Arch Dermatol"},{"key":"1662_CR13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20030451","volume":"199","author":"Lee","year":"2005","unstructured":"Lee E, Trepicchio WL, Oestreicher JL et al (2005) Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199:125\u2013130","journal-title":"J Exp Med"},{"key":"1662_CR14","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"Leonardi","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371:1665\u20131674","journal-title":"Lancet"},{"key":"1662_CR15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1517\/14728222.9.2.225","volume":"9","author":"Ludwig","year":"2005","unstructured":"Ludwig R, Sch\u00f6n MP (2005) Lymphocyte trafficking to inflamed skin \u2013 molecular mechanisms and implications for therapeutic target molecules. Expert Opin Ther Targets 9:225\u2013243","journal-title":"Expert Opin Ther Targets"},{"key":"1662_CR16","unstructured":"Magliocco MA, Gottlieb AB (2005) 63rd Annual Meeting of the American Academy of Dermatology: 2005 February 18\u201322, New Orleans"},{"key":"1662_CR17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s00393-006-0132-6","volume":"66","author":"Manger","year":"2007","unstructured":"Manger B, Michels H, N\u00fcsslein et al (2007) Revision of the recommendations of the commission on pharmacotherapy of the german society for rheumatology: therapy with tumor necrosis factor blockers for inflammatory rheumatic illnesses. Z Rheumatol 66:72\u201375","journal-title":"Z Rheumatol"},{"key":"1662_CR18","doi-asserted-by":"crossref","unstructured":"Nast A, Kopp IB, Augustin M et al (2006) S3-Leitlinie zur Therapie der Psoriasis-vulgaris, J Dtsch Dermatol Ges 4:1\u2013216","DOI":"10.1111\/j.1610-0387.2006.06172.x"},{"key":"1662_CR19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","volume":"55","author":"Neimann","year":"2006","unstructured":"Neimann AL, Shin DB, Wang X et al (2006) Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55:829\u2013835","journal-title":"J Am Acad Dermatol"},{"key":"1662_CR20","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1172\/JCI200422147","volume":"113","author":"Nickoloff","year":"2004","unstructured":"Nickoloff BJ, Nestle FO (2004) Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 113:1664\u20131675","journal-title":"J Clin Invest"},{"key":"1662_CR21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa066886","volume":"358","author":"Paller","year":"2008","unstructured":"Paller AS, Siegfried EC, Langley RG et al (2008) Etanercept treatment for children and adolescents with plaque psoriasis. N Eng J Med 358:241\u2013251","journal-title":"N Eng J Med"},{"key":"1662_CR22","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0140-6736(08)60593-0","volume":"371","author":"Papp","year":"2008","unstructured":"Papp KA, Bissonnette R, Rosoph L et al (2008) Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet 371:1337\u20131342","journal-title":"Lancet"},{"key":"1662_CR23","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a rondomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371:1675\u20131684","journal-title":"Lancet"},{"key":"1662_CR24","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1610-0387.2007.06343.x","volume":"7","author":"Reich","year":"2007","unstructured":"Reich K, Mrowietz U (2007) Therapieziele bei der Behandlung der Psoriasis. JDDG 7:566\u2013575","journal-title":"JDDG"},{"key":"1662_CR25","unstructured":"Philipp S (2008) Psoriasis-Therapieversuch mit dem Panselektin-Antagonisten TBC1269Z. Dissertationsschrift Medizinische Fakult\u00e4t Charit\u00e9 \u2013 Universit\u00e4tsmedizin, Berlin"},{"key":"1662_CR26","doi-asserted-by":"crossref","unstructured":"Sch\u00e4kel K (2008) Dendritic cells \u2013 why can they help and hurt us? Exp Dermatol (in press)","DOI":"10.1111\/j.1600-0625.2008.00823.x"},{"key":"1662_CR27","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMra041320","volume":"352","author":"Sch\u00f6n","year":"2005","unstructured":"Sch\u00f6n MP, Boehncke WH (2005) Psoriasis. N Engl J Med 352:1899\u20131912","journal-title":"N Engl J Med"},{"key":"1662_CR28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.0906-6705.2004.00205.x","volume":"13","author":"Schottelius","year":"2004","unstructured":"Schottelius AJG, Moldawer LL, Dinarello CA et al (2004) Biology of tumor necrosis factor-\u03b1-implications for psoriasis. Exp Dermatol 13:193\u2013222","journal-title":"Exp Dermatol"},{"key":"1662_CR29","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000083509","volume":"210","author":"Schmitt","year":"2005","unstructured":"Schmitt J, Wozel G (2005) The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 210:194\u20131999","journal-title":"Dermatology"},{"key":"1662_CR30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2133.2008.08732.x","volume":"159","author":"Schmitt","year":"2008","unstructured":"Schmitt J, Zhengguang Z, Wozel G et al (2008) Efficacy and tolerability of biologic and non-biologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 159:513\u2013526","journal-title":"Br J Dermatol"},{"key":"1662_CR31","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"Taylor","year":"2006","unstructured":"Taylor W, Gladmann D, Helliwell P et al (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665\u20132673","journal-title":"Arthritis Rheum"},{"key":"1662_CR32","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"Tracey","year":"2008","unstructured":"Tracey D, Klareskog L, Sasso EH et al (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117:244\u2013279","journal-title":"Pharmacol Ther"},{"key":"1662_CR33","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1074-7613(03)00296-6","volume":"19","author":"Trinchieri","year":"2003","unstructured":"Trinchieri G, Pflanz S, Kastelein RA (2003) The IL-12 family of heterodimeric cytokines: new players in the regulation of T Cell responses. Immunity 19:641\u2013644","journal-title":"Immunity"},{"key":"1662_CR34","first-page":"1177","volume":"159","author":"van","year":"2008","unstructured":"van de Kerkhof PC, Segaert S, Lahfa M et al (2008) Once weekly administration of etanercept 50\u00a0mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 159:1177\u20131185","journal-title":"Br J Dermatol"},{"key":"1662_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00128071-200809010-00001","volume":"9","author":"Wollina","year":"2008","unstructured":"Wollina U, Hansel G, Koch A et al (2008) Tumor necrosis factor-\u03b1 inhibitor-induced psoriasis or psoriasiform exanthemata. Am J Clin Dermatol 9:1\u201314","journal-title":"Am J Clin Dermatol"},{"key":"1662_CR36","unstructured":"Wozel G, Jahn S (2006) Biologics in der Dermatologie, 2.\u00a0Auf. Uni-Med, Bremen London Boston"},{"key":"1662_CR37","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2340\/00015555-0361","volume":"Venereol","author":"Wozel","year":"2008","unstructured":"Wozel G, Vit\u00e9z L (2008) Palmoplantar pustular psoriasis \u2013 successful therapy with efalizumab after non-response to infliximab. Acta Derm Venereol (Stockh) 88:169\u2013170","journal-title":"Acta Derm"},{"key":"1662_CR38","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/0091270006298188","volume":"47","author":"Zhou","year":"2007","unstructured":"Zhou H, Jang J, Fleischmann RM et al (2007) Pharmacokinetics and safety of golimumab, a fully human anti-TNF-\u03b1 monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 47:383\u2013396","journal-title":"J Clin Pharmacol"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-008-1662-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-008-1662-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-008-1662-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T23:37:40Z","timestamp":1558568260000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-008-1662-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,30]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["1662"],"URL":"https:\/\/doi.org\/10.1007\/s00105-008-1662-4","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,30]]}}}